Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
22 studies found for:    MAJOR AFFECTIVE DISORDER 5
Show Display Options
Rank Status Study
1 Completed A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
2 Completed 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
Condition: Major Depressive Disorder
Intervention: Drug: 5-hydroxytryptophan and Creatine monohydrate
3 Recruiting Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Vortioxetine;   Drug: Placebo
4 Recruiting Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
Condition: Major Depressive Disorder
Interventions: Drug: 5-hydroxytryptophan and Creatine;   Other: Placebo control
5 Withdrawn Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder
Conditions: Major Depression;   Unipolar Depression;   Depression;   Anxiety Disorder
Intervention: Other: Antidepressant (SSRI)
6 Completed Effect of Physical Activity on Depressive Symptoms With a 5 Month Follow-up
Condition: Major Depressive Disorder
Intervention: Other: Physical activity program
7 Completed
Has Results
Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
Condition: Major Depressive Disorder
Intervention: Drug: Vortioxetine (Lu AA21004)
8 Completed
Has Results
Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
Condition: Major Depressive Disorder
Intervention: Drug: Vortioxetine (Lu AA21004)
9 Completed
Has Results
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Placebo;   Drug: Vortioxetine (Lu AA21004);   Drug: Duloxetine
10 Completed
Has Results
Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
Condition: Major Depressive Disorder
Interventions: Drug: Placebo;   Drug: Vortioxetine (Lu AA21004);   Drug: Venlafaxine XL
11 Completed Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Conditions: Major Depressive Disorder;   Anxiety Disorders
Intervention: Drug: Hydrocortisone
12 Completed
Has Results
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
Condition: Major Depressive Disorder
Interventions: Drug: Placebo;   Drug: Vortioxetine (Lu AA21004);   Drug: Duloxetine
13 Completed Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
Condition: Major Depressive Disorder
Intervention: Drug: Mecamylamine
14 Recruiting Examination of Glutamate and mGluR5 in Psychiatric Disorders
Conditions: Major Depressive Disorder;   Post-Traumatic Stress Disorder;   Bipolar Disorder
Interventions: Behavioral: Cognitive Testing;   Other: MRI;   Radiation: PET
15 Completed PET Imaging of mGLuR5 With Drug Challenge
Conditions: Major Depressive Disorder;   Post-Traumatic Stress Disorder (PTSD)
Intervention: Drug: Ketamine
16 Active, not recruiting rTMS for PTSD Comorbid With Major Depressive Disorder
Conditions: Posttraumatic Stress Disorder;   Major Depressive Disorder;   Transcranial Magnetic Stimulation, Repetitive
Intervention: Device: Transcranial Magnetic Stimulation
17 Completed PET Whole Body Distribution Studies Using [11C]CUMI
Conditions: Depression;   Major Depression;   Unipolar Depression;   Anxiety Disorder;   Anxiety Disorders
Intervention:
18 Not yet recruiting Treatment Outcome in Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Duloxetine
19 Completed An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
Condition: Depressive Disorder
Intervention: Drug: MDL100.907
20 Withdrawn The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives
Conditions: Major Depressive Disorder;   Anxiety;   Comorbidity
Interventions: Drug: Vilazodone;   Drug: Citalopram

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.